Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Arsenic Trioxide and Itraconazole for Advanced BCC
NCT02699723Phase 1Withdrawn
- Start
- Dec 2020
- Primary completion
- Sep 2021
- Modality
- DNA Intercalators/Alkylators, Orthosteric Ligands
01
Overview
Phase 1, open-label trial of arsenic trioxide and itraconazole in basal cell carcinoma (BCC). Planned start Dec 2020; status: withdrawn.
02
Drugs
arsenic trioxideitraconazole
03
Conditions
basal cell carcinoma (BCC)
Beyond the preview
Go deeper on NCT02699723.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02699723.